You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Merck
Dow
Moodys
Boehringer Ingelheim

Last Updated: February 25, 2024

Dalbavancin hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for dalbavancin hydrochloride and what is the scope of freedom to operate?

Dalbavancin hydrochloride is the generic ingredient in one branded drug marketed by Abbvie and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dalbavancin hydrochloride has fifty-eight patent family members in twenty countries.

One supplier is listed for this compound.

Summary for dalbavancin hydrochloride
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for dalbavancin hydrochloride
Generic Entry Date for dalbavancin hydrochloride*:
Constraining patent/regulatory exclusivity:
NEW PATIENT POPULATION
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for dalbavancin hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Wake Forest University Health SciencesPhase 4
ADVANZ PHARMAPhase 3
Nantes University HospitalPhase 3

See all dalbavancin hydrochloride clinical trials

Pharmacology for dalbavancin hydrochloride

US Patents and Regulatory Information for dalbavancin hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Abbvie DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Abbvie DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for dalbavancin hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 ⤷  Try a Trial ⤷  Try a Trial
Abbvie DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 ⤷  Try a Trial ⤷  Try a Trial
Abbvie DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for dalbavancin hydrochloride

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2006078277 ⤷  Try a Trial
Israel 178207 תכשירים רוקחיים המכילים דלבאוואנצין ו/או מנוזיל אגליקון לטיפול בזיהומים חיידקיים (Pharmaceutical compositions comprising dalbavancin and/or mannosyl aglycone for the treatment of bacterial infections) ⤷  Try a Trial
European Patent Office 1565201 PROCEDES D'ADMINISTRATION DE DALBAVANCINE DANS LE TRAITEMENT D'INFECTIONS BACTERIENNES (METHODS OF ADMINISTERING DALBAVANCIN FOR TREATMENT OF BACTERIAL INFECTIONS) ⤷  Try a Trial
Spain 2712656 ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 2004046196 ⤷  Try a Trial
Russian Federation 2008142899 КОМПОЗИЦИИ ДАЛБАВАНЦИНА ДЛЯ ЛЕЧЕНИЯ БАКТЕРИАЛЬНЫХ ИНФЕКЦИЙ ⤷  Try a Trial
Israel 239913 שימוש בדלבאוואנצין בנשא רוקחי מקובל בייצור תרופה לטיפול בזיהומים חיידקים (Use of dalbavancin in a pharmaceutically acceptable carrier in the manufacture of a medicament for treating bacterial infections) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Colorcon
Harvard Business School
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.